cp-12
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 12, 2025 (NCT06814717)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetINHIBITOR
GAPDH
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSSM5MFZ7FKP ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06814717 | Phase 2 | May 12, 2025 | Department of Defense, Georgetown University, Neomatrix Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| Georgetown University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Neomatrix Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1